Recombinant Rat TGF-beta receptor type-2 (Tgfbr2)

How does TGFBR2 function in the TGF-β signaling pathway?

TGFBR2 functions as an essential component of the TGF-β signaling cascade. Upon TGF-β ligand binding, TGFBR2 forms a heteromeric complex with TGFBR1, initiating signal transduction. In this signaling mechanism:

• TGF-β ligands first bind to TGFBR2, often facilitated by the accessory receptor betaglycan (TGF-β receptor III)

• TGFBR2 then recruits and phosphorylates TGFBR1 (also known as ALK-5)

• Activated TGFBR1 propagates the signal by phosphorylating downstream Smad proteins

• Phosphorylated Smads translocate to the nucleus and regulate gene transcription

Importantly, both TGFBR2 and TGFBR1 are required for proper signal transduction, and genetic studies have demonstrated that conditional deletion of either receptor can lead to similar phenotypes in specific tissues, such as the female reproductive tract .

What are the differences between rat TGFBR2 and human TGFBR2?

While rat and human TGFBR2 share significant homology, researchers should be aware of species-specific differences that may impact experimental outcomes. The high degree of conservation across mammalian species suggests functional similarity, but subtle structural variations may affect ligand binding affinity and downstream signaling efficiency. When designing cross-species experiments, consider that:

• Both receptors maintain the core structural elements required for TGF-β binding and signal transduction

• Species-specific post-translational modifications may affect receptor activity

• Cross-reactivity of antibodies and ligands should be validated experimentally

• Expression patterns may vary across analogous tissues in different species

What are the optimal reconstitution protocols for recombinant rat TGFBR2?

For optimal reconstitution of recombinant rat TGFBR2, follow these methodological steps:

• Centrifuge the vial briefly before opening to ensure all material is at the bottom

• For lyophilized protein:

  • Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL

  • Add glycerol to a final concentration of 5-50% (recommended final concentration: 50%)

  • Mix gently until completely dissolved

• For long-term storage:

  • Aliquot the reconstituted protein into small volumes to avoid repeated freeze-thaw cycles

  • Store at -20°C or preferably -80°C

• Avoid repeated freeze-thaw cycles that can denature the protein and reduce activity

When using the reconstituted protein in experiments, it's advisable to perform a small-scale test to ensure biological activity is maintained under your specific experimental conditions.

How can researchers validate the functionality of recombinant TGFBR2?

Validating the functionality of recombinant rat TGFBR2 is critical before performing complex experiments. Consider these methodological approaches:

• Binding assays:

  • Use labeled TGF-β ligands (TGF-β1, TGF-β2, or TGF-β3) to confirm binding

  • Employ surface plasmon resonance (SPR) to determine binding kinetics and affinity constants

  • Competitive binding assays with known TGFBR2 ligands

• Signal transduction assays:

  • Monitor Smad2/3 phosphorylation in cell-based systems

  • Use reporter cell lines containing Smad-responsive elements

  • Measure induction of known TGF-β target genes

• Co-immunoprecipitation:

  • Verify interaction with TGFBR1 following ligand binding

  • Confirm complex formation with accessory proteins like betaglycan

• Functional inhibition:

  • Test the ability of the recombinant receptor to act as a ligand trap and inhibit TGF-β signaling

  • Validate with established cellular responses such as the inhibition of IL-4-induced cell proliferation in mouse T cell lines

What considerations are important for designing TGFBR2 knockout experiments?

When designing experiments involving TGFBR2 knockout models, researchers should consider:

• Choice of knockout strategy:

  • Conditional vs. global knockout (global knockouts are often embryonic lethal)

  • Tissue-specific promoters for conditional deletion (e.g., Amhr2-Cre for female reproductive tract studies)

  • Temporal control using inducible systems

• Phenotypic analysis timeline:

  • Developmental time points for assessment (e.g., postnatal days 3, 10, 14, 21, and 28 for intestinal studies)

  • Age-dependent changes in receptor expression patterns

  • Persistent vs. transient phenotypes

• Functional redundancy assessment:

  • Examine potential compensatory upregulation of related receptors

  • Consider double knockouts (e.g., TGFBR1/TGFBR2) to understand functional redundancy

  • Analyze expression of downstream signaling components

• Phenotypic characterization:

  • Immunohistochemical analysis of tissue structure

  • Cell marker expression to identify affected cell populations

  • Molecular analysis of altered gene expression patterns

Studies with Tgfbr2 conditional knockout mice have revealed that deletion using the same Cre driver as for Tgfbr1 deletion results in similar phenotypic outcomes, suggesting functional similarity between these receptors in maintaining structural integrity of tissues such as the female reproductive tract .

What methods are recommended for analyzing TGFBR2 expression in tissue samples?

For comprehensive analysis of TGFBR2 expression in tissue samples, employ multiple complementary techniques:

• Immunohistochemistry/Immunofluorescence:

  • Allows visualization of spatial distribution within tissues

  • Can reveal cell-specific expression patterns

  • Enables co-localization studies with cell type markers

  • Important for developmental studies, as receptor distribution changes with age

• Quantitative RT-PCR:

  • Provides precise quantification of mRNA expression levels

  • Enables comparison across different tissues or treatment conditions

  • Should include appropriate reference genes for normalization

• Western blotting:

  • Confirms protein expression and size

  • Can detect both monomeric (reduced conditions) and dimeric forms (non-reduced conditions)

  • Should include positive controls such as commercial recombinant TGFBR2

• Flow cytometry:

  • Quantifies receptor expression at the single-cell level

  • Allows for sorting of receptor-positive cell populations

  • Useful for heterogeneous tissue analysis

When analyzing TGFBR2 expression, it's important to note that expression patterns change developmentally. For example, in rat intestinal tissue, receptor expression varies with age, with receptor II predominantly expressed in the crypt, and staining on the villi appearing after day 10 of postnatal development .

How can researchers distinguish between TGFBR2 and other TGF-β receptor types?

Distinguishing between different TGF-β receptor types requires careful experimental design:

• Antibody selection:

  • Use highly specific antibodies validated for the receptor of interest

  • Confirm specificity using receptor knockout controls or siRNA-treated samples

  • Consider using multiple antibodies targeting different epitopes

• Expression pattern analysis:

  • Different receptor types show distinct tissue and developmental expression patterns

  • For example, in rat intestine:

    • Receptor I: expressed on apical and basolateral membranes of villus and crypt epithelium

    • Receptor II: predominantly expressed in the crypt

    • Receptor III: distributed throughout the mucosa at early ages but diminishes from epithelium postweaning

• Functional assays:

  • Use receptor-specific ligands or inhibitors

  • TGFBR2 directly binds TGF-β ligands, while TGFBR1 requires TGFBR2 for ligand binding

  • Receptor III (betaglycan) binds and presents TGF-β1 or β2 to receptor II

• Molecular weight determination:

  • TGFBR2 has a different molecular weight than other receptor types

  • Under reducing conditions, recombinant human TGF-β2 shows a band at 12 kDa

  • Under non-reducing conditions, it shows a band at 24 kDa

How can researchers investigate TGFBR2 mutations in disease models?

Investigation of TGFBR2 mutations in disease models requires a multi-faceted approach:

• Identification of relevant mutations:

  • Literature review of disease-associated TGFBR2 mutations

  • Genetic screening of patient samples

  • Analysis of public databases such as GWAS studies

• Generation of mutation models:

  • CRISPR/Cas9 gene editing to introduce specific mutations

  • Site-directed mutagenesis of recombinant TGFBR2 constructs

  • Patient-derived cell models or organoids

• Functional characterization:

  • Ligand binding assays to assess receptor-ligand interaction

  • TGFBR1 interaction studies to evaluate complex formation

  • Downstream signaling analysis focusing on Smad phosphorylation

  • Transcriptional profiling to identify altered gene expression patterns

• Phenotypic analysis:

  • Tissue-specific effects of mutations

  • Developmental consequences in animal models

  • Correlation with disease progression

For example, studies have identified TGFBR2 variants associated with breast cancer risk. The SNP rs1078985 in TGFBR2 showed significant associations with breast cancer risk, with both heterozygotes and homozygotes having significantly lower risks compared to major allele homozygotes .

What protocols are recommended for studying TGFBR2-TGFBR1 interactions?

To effectively study TGFBR2-TGFBR1 interactions, consider these methodological approaches:

• Co-immunoprecipitation studies:

  • Express tagged versions of both receptors in cell systems

  • Immunoprecipitate one receptor and detect co-precipitation of the other

  • Include controls with ligand stimulation vs. no stimulation

  • Use antibodies specific to the tags or to the receptors themselves

• FRET/BRET analysis:

  • Label TGFBR2 and TGFBR1 with appropriate fluorophores or bioluminescent tags

  • Monitor energy transfer as a measure of receptor proximity

  • Quantify changes in energy transfer upon ligand binding

• Proximity ligation assay:

  • Visualize receptor interactions in situ in tissue sections

  • Quantify interaction events at the single-cell level

  • Compare interaction patterns across different tissues or conditions

• Functional complementation studies:

  • Use cells lacking endogenous receptors

  • Co-express wild-type and mutant forms of receptors

  • Assess restoration of signaling as a measure of functional interaction

How do different TGF-β ligands interact with recombinant rat TGFBR2?

The interaction between different TGF-β ligands and recombinant rat TGFBR2 exhibits specific characteristics that researchers should consider:

• Ligand-specific binding kinetics:

  • TGF-β1, TGF-β2, and TGF-β3 may bind with different affinities

  • Binding assays should be performed for each ligand separately

  • SPR analysis can provide quantitative binding parameters

• Co-receptor requirements:

  • TGF-β2 typically requires betaglycan (TGFBR3) for efficient binding to TGFBR2

  • TGF-β1 and TGF-β3 can bind directly to TGFBR2 with high affinity

  • Experimental design should account for these differences

• Signaling outcomes:

  • Different ligands may induce qualitatively different signaling responses

  • Phosphorylation patterns of downstream Smads may vary

  • Gene expression profiles should be compared across ligands

• Functional readouts:

  • TGF-β2 has been shown to inhibit IL-4-induced cell proliferation in mouse T cell lines with an ED50 of 0.025-0.25 ng/mL

  • Similar functional assays can be used to compare potency of different ligands

  • Cell type-specific responses should be considered

How can researchers troubleshoot issues with recombinant TGFBR2 stability?

When encountering stability issues with recombinant rat TGFBR2, consider these troubleshooting approaches:

• Storage conditions optimization:

  • Use a manual defrost freezer to avoid temperature fluctuations

  • Store reconstituted protein with 5-50% glycerol as a cryoprotectant

  • Maintain consistent storage temperature (-20°C or -80°C)

  • Avoid repeated freeze-thaw cycles

• Buffer composition adjustment:

  • For reconstitution, use sterile 4 mM HCl containing human or bovine serum albumin

  • For lyophilized protein, reconstitute in appropriate buffer (e.g., Tris/PBS-based buffer)

  • Consider testing different pH values to optimize stability

  • Add protease inhibitors if degradation is observed

• Protein handling practices:

  • Work with the protein on ice when possible

  • Centrifuge vials briefly before opening

  • Use low-binding tubes for storage

  • Filter sterilize solutions if microbial contamination is a concern

• Functional validation:

  • Perform binding assays before and after storage to monitor activity

  • Use positive controls with known activity

  • Consider including carrier proteins if protein concentration is low

Lyophilized recombinant proteins typically have longer shelf lives than solutions. The lyophilized form of recombinant rat TGFBR2 is often prepared in Tris/PBS-based buffer with 6% Trehalose at pH 8.0 to maintain stability during the lyophilization process .

What controls should be included in experiments using recombinant TGFBR2?

Robust experimental design with appropriate controls is essential when working with recombinant TGFBR2:

• Positive controls:

  • Commercial recombinant TGFBR2 with verified activity

  • Cell lines with known TGFBR2 expression and responsiveness

  • Positive ligand-receptor interaction (e.g., TGF-β1 binding to TGFBR2)

• Negative controls:

  • Heat-inactivated recombinant protein

  • Non-specific proteins with similar tags

  • TGFBR2-knockout or depleted cells

  • Blocking antibodies against TGF-β ligands

• Specificity controls:

  • Competition assays with unlabeled ligands

  • Non-relevant cytokine receptors to demonstrate specificity

  • Tag-only proteins to control for tag-specific effects

• Technical controls:

  • Protein concentration normalization

  • SDS-PAGE analysis under reducing and non-reducing conditions to confirm protein integrity

  • Western blot analysis to verify protein size and expression

  • Bradford or BCA assays for accurate protein quantification

For SDS-PAGE analysis, recombinant human TGF-beta 2 resolved under reducing conditions shows a single band at 12 kDa, while under non-reducing conditions it shows a band at 24 kDa . Similar analysis can be performed for recombinant rat TGFBR2 to confirm proper protein structure before experimental use.